AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02718300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
Study NCT02718300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
Study NCT02718300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: 20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
Study NCT02718300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: 2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily.
Study NCT01036061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Low Dose
Description: GSK618334 low dose
Study NCT01036061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 PET subjects
Description: PET subjects
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic pulse-wave velocity
Description: Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aortic pulse-wave velocity
Description: Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
Study NCT02112266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mail support
Description: between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
Study NCT02112266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no mail support
Description: follow-up without mail support
Study NCT04419506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
Study NCT04419506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Study NCT01036061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 Medium Dose
Description: Medium Dose
Study NCT01036061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334 High Dose
Description: GSK618334 High Dose
Study NCT05635058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Reminisence Therapy
Description: Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
Study NCT04396054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lag Screws
Description: Method of internal fixation
Study NCT04396054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double Y-shaped plates
Description: Method of internal fixation
Study NCT04727112 — intervention group
Intervention type: DRUG
Intervention: Usual care versus primary care
Description: RCT study
Study NCT03792919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop current treatment (anti-HBV neucleos(t)ides)
Description: Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Study NCT03792919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keep current treatment (anti-HBV neucleos(t)ides)
Description: Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Study NCT03901183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Diet
Description: Patients are guided to change their nutrition to a plant-based diet.
Study NCT03614624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips
Description: Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
Study NCT02291380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A for Injection
Description: In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
Study NCT02291380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
Study NCT04995744 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis Major Pedicle Bone Graft
Description: It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
Study NCT02360943 — intervention group
Intervention type: OTHER
Intervention: 4 blood samples
Description: PK and / or PD measurements during hospitalization
Study NCT01226667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly.
Study NCT02732912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear plugs
Description: The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
Study NCT02732912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Mask
Description: The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
Study NCT02732912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: This night sedation will be given to any patient requesting it, in either group
Study NCT02732912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: This night sedation will be given to any patient requesting it, in either group
Study NCT04382651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: MAS825 liquid solution for intravenous infusion
Study NCT04382651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid solution for intravenous infusion
Study NCT04382651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study NCT04382651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Study NCT02924753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Study NCT02924753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
Study NCT02924753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study NCT02221427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic progression curve
Description: Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
Study NCT02221427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static labour progression curve (F)
Study NCT02439762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
Study NCT02439762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psycho-education (SPC)
Description: This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
Study NCT00211822 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI
Description: fMRI
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opana then darvocet then placebo
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opana then placebo then darvocet
Description: Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo then opana then darvocet
Description: Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then darvocet then opana
Description: Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darvocet then opana then placebo
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
Study NCT00652093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darvocet then placebo then opana
Description: Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
Study NCT01411540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole grains
Description: Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
Study NCT01411540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grains
Description: Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
Study NCT04046484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
Study NCT04046484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study NCT02796950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: P.o. administration of 250 mg acipimox
Study NCT04486521 — intervention group
Intervention type: DRUG
Intervention: Interleukin 6 (IL6) Antagonist
Description: anti-IL6 alone
Study NCT04486521 — intervention group
Intervention type: DRUG
Intervention: Interleukin 6 (IL6) Antagonist and corticosteroids
Description: anti-IL6 + corticosteroid combination
Study NCT03342339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Iowa Gambling Task
Description: Test of Iowa Gambling Task
Study NCT01266902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: 25 mg once daily
Study NCT04486521 — intervention group
Intervention type: DRUG
Intervention: corticosteroid alone
Description: dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent
Study NCT00956644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/amlodipine
Description: Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
Study NCT00956644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
Study NCT02820714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 Laxative
Study NCT00570232 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg per day by mouth for 12 months
Study NCT05151627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KINESIO TAPING
Description: Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
Study NCT05151627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL PHYSICAL THERAPY
Description: Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions.
Study NCT03784534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
Study NCT03784534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and behavioral testing : Motor recovery progress
Description: NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
Study NCT03784534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and behavioral testing : Motor skills
Description: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
Study NCT03586219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid-specific educational patient pamphlets
Description: See prior description
Study NCT01316536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: provide headphones with music playing
Description: Participants will be provided with music through headphones
Study NCT01316536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sounds
Description: recorded ICU sounds will be provided to participants through headphones
Study NCT00095537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panHer
Description: Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
Study NCT03407209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of local anesthetic measurement
Description: consumption of local anesthetic measurement in both groups
Study NCT03407209 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: consumption of local anesthetic measurement
Description: consumption of local anesthetic measurement in both groups
Study NCT03201003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101 powder provided in capsules & sachets
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Study NCT03201003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules & sachets
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial cell collection
Description: Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
Study NCT02209636 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial cell collection
Description: Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
Study NCT00985452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GlowCaps Connect system
Description: The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.